About our company

Adjutec Pharma AS is a Norwegian pharmaceutical start-up company. It was founded in 2019. The management and operational structure are established, with key competencies well represented.

The company vision is to develop and provide novel antibiotic resistance breakers in order to retain efficacy and facilitate reduced use of antibiotics.
Adjutec Pharma's lead product is a metallo-β-lactamase resistance breaker, APC148.

APC148 has demonstrated efficacy against a large panel of multidrug resistant isolates, the synthesis route is simple and scalable, and preliminary in vitro tests indicate a favourable toxicity profile.